Cargando…
Reviewing the quality, health benefit and value for money of chemotherapy and targeted therapy for metastatic breast cancer
PURPOSE: To provide an overview of model characteristics and outcomes of model-based economic evaluations concerning chemotherapy and targeted therapy (TT) for metastatic breast cancer (MBC); to assess the quality of the studies; to analyse the association between model characteristics and study qua...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5602061/ https://www.ncbi.nlm.nih.gov/pubmed/28689361 http://dx.doi.org/10.1007/s10549-017-4374-6 |
_version_ | 1783264513961754624 |
---|---|
author | Pouwels, Xavier Ghislain Léon Victor Ramaekers, Bram L. T. Joore, Manuela A. |
author_facet | Pouwels, Xavier Ghislain Léon Victor Ramaekers, Bram L. T. Joore, Manuela A. |
author_sort | Pouwels, Xavier Ghislain Léon Victor |
collection | PubMed |
description | PURPOSE: To provide an overview of model characteristics and outcomes of model-based economic evaluations concerning chemotherapy and targeted therapy (TT) for metastatic breast cancer (MBC); to assess the quality of the studies; to analyse the association between model characteristics and study quality and outcomes. METHODS: PubMED and NHS EED were systematically searched. Inclusion criteria were as follows: English or Dutch language, model-based economic evaluation, chemotherapy or TT as intervention, population diagnosed with MBC, published between 2000 and 2014, reporting life years (LY) or quality-adjusted life-year (QALY) and an incremental cost-effectiveness ratio. General characteristics, model characteristics and outcomes of the studies were extracted. Quality of the studies was assessed through a checklist. RESULTS: 24 studies were included, considering 50 comparisons (20 concerning chemotherapy and 30 TT). Seven comparisons were represented in multiple studies. A health state-transition model including the following health states: stable/progression-free disease, progression and death was used in 18 studies. Studies fulfilled on average 14 out of the 26 items of the quality checklist, mostly due to a lack of transparency in reporting. Thirty-one per cent of the incremental net monetary benefit was positive. TT led to higher iQALY gained, and industry-sponsored studies reported more favourable cost-effectiveness outcomes. CONCLUSIONS: The development of a disease-specific reference model would improve the transparency and quality of model-based cost-effectiveness assessments for MBC treatments. Incremental health benefits increased over time, but were outweighed by the increased treatment costs. Consequently, increased health benefits led to lower value for money. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s10549-017-4374-6) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5602061 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-56020612017-10-04 Reviewing the quality, health benefit and value for money of chemotherapy and targeted therapy for metastatic breast cancer Pouwels, Xavier Ghislain Léon Victor Ramaekers, Bram L. T. Joore, Manuela A. Breast Cancer Res Treat Review PURPOSE: To provide an overview of model characteristics and outcomes of model-based economic evaluations concerning chemotherapy and targeted therapy (TT) for metastatic breast cancer (MBC); to assess the quality of the studies; to analyse the association between model characteristics and study quality and outcomes. METHODS: PubMED and NHS EED were systematically searched. Inclusion criteria were as follows: English or Dutch language, model-based economic evaluation, chemotherapy or TT as intervention, population diagnosed with MBC, published between 2000 and 2014, reporting life years (LY) or quality-adjusted life-year (QALY) and an incremental cost-effectiveness ratio. General characteristics, model characteristics and outcomes of the studies were extracted. Quality of the studies was assessed through a checklist. RESULTS: 24 studies were included, considering 50 comparisons (20 concerning chemotherapy and 30 TT). Seven comparisons were represented in multiple studies. A health state-transition model including the following health states: stable/progression-free disease, progression and death was used in 18 studies. Studies fulfilled on average 14 out of the 26 items of the quality checklist, mostly due to a lack of transparency in reporting. Thirty-one per cent of the incremental net monetary benefit was positive. TT led to higher iQALY gained, and industry-sponsored studies reported more favourable cost-effectiveness outcomes. CONCLUSIONS: The development of a disease-specific reference model would improve the transparency and quality of model-based cost-effectiveness assessments for MBC treatments. Incremental health benefits increased over time, but were outweighed by the increased treatment costs. Consequently, increased health benefits led to lower value for money. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s10549-017-4374-6) contains supplementary material, which is available to authorized users. Springer US 2017-07-08 2017 /pmc/articles/PMC5602061/ /pubmed/28689361 http://dx.doi.org/10.1007/s10549-017-4374-6 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Review Pouwels, Xavier Ghislain Léon Victor Ramaekers, Bram L. T. Joore, Manuela A. Reviewing the quality, health benefit and value for money of chemotherapy and targeted therapy for metastatic breast cancer |
title | Reviewing the quality, health benefit and value for money of chemotherapy and targeted therapy for metastatic breast cancer |
title_full | Reviewing the quality, health benefit and value for money of chemotherapy and targeted therapy for metastatic breast cancer |
title_fullStr | Reviewing the quality, health benefit and value for money of chemotherapy and targeted therapy for metastatic breast cancer |
title_full_unstemmed | Reviewing the quality, health benefit and value for money of chemotherapy and targeted therapy for metastatic breast cancer |
title_short | Reviewing the quality, health benefit and value for money of chemotherapy and targeted therapy for metastatic breast cancer |
title_sort | reviewing the quality, health benefit and value for money of chemotherapy and targeted therapy for metastatic breast cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5602061/ https://www.ncbi.nlm.nih.gov/pubmed/28689361 http://dx.doi.org/10.1007/s10549-017-4374-6 |
work_keys_str_mv | AT pouwelsxavierghislainleonvictor reviewingthequalityhealthbenefitandvalueformoneyofchemotherapyandtargetedtherapyformetastaticbreastcancer AT ramaekersbramlt reviewingthequalityhealthbenefitandvalueformoneyofchemotherapyandtargetedtherapyformetastaticbreastcancer AT jooremanuelaa reviewingthequalityhealthbenefitandvalueformoneyofchemotherapyandtargetedtherapyformetastaticbreastcancer |